Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Specimen Handling 71Magnetic Resonance Spectroscopy 57Biopsy 44pembrolizumab 38Carboplatin 32Nivolumab 29Cyclophosphamide 27Radiotherapy 26Radiation 25Paclitaxel 24Cisplatin 24olaparib 21Etoposide 19Doxorubicin 18durvalumab 17Taxes 17Radiotherapy, Intensity-Modulated 17Dexamethasone 17Bevacizumab 17X-Rays 16Vincristine 16Prednisone 16Immunoglobulin G 16Disulfides 16Cytarabine 15Platinum 14Leucovorin 14Docetaxel 14Pemetrexed 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × 130-nm albumin-bound paclitaxel × 30 days × Clear all
NCT06119217 2026-05-13

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Trishula Therapeutics, Inc.

Phase 2 Completed
194 enrolled 16 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT04251533 2026-05-11

EPIK-B3

Novartis

Phase 3 Terminated
137 enrolled 21 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡